Targeting eosinophilic esophagitis

Targeting eosinophilic esophagitis

Dupilumab improves histologic, symptomatic, and endoscopic outcomes in eosinophilic esophagitis, regardless of history of food allergy or food elimination diets

Dupilumab improves type 2 comorbidity outcomes in patients with eosinophilic esophagitis and history of comorbid disease at baseline: Results from Parts A and B of LIBERTY-EoE-TREET

Effect of dupilumab treatment on inflammatory type 2 biomarkers in patients with eosinophilic esophagitis: Part B of LIBERTY-EoE-TREET

Granzyme B is elevated in esophageal biopsies in Pediatric Eosinophilic Esophagitis